Review



dexcom cgm sensor  (Dexcom Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Dexcom Inc dexcom cgm sensor
    Dexcom Cgm Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/cgm+sensors/pm42156180-52-2-2
    Average 86 stars, based on 1 article reviews
    dexcom cgm sensor - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020–2023): a longitudinal multicentre real-world study
    Article Snippet: In a cross-over RCT, Ware et al. reported that the CamAPS FX closed-loop system using a Dexcom sensor achieved a TIR of 71.6% after 16 weeks in 74 children aged 1–7 years.

    Article Title: How to compare algorithms for automated insulin delivery using different sensors?
    Article Snippet: Recent caution has been advised against comparing automatic insulin delivery (AID) systems that use different sensors.. While the same two AID systems (Tandem Control IQ (CoIQ) and Minimed 780 G (MM780G)) have shown clear differences in time in range (TIR) outcomes, studies report no clinically relevant difference in HbA1c or only minimal changes in HbA1c and TIR.. A simplified overview of these four studies is presented in Table 1.

    Article Title: Impact of Automated Insulin Delivery Systems in Children and Adolescents with Type 1 Diabetes Previously Treated with Multiple Daily Injections: A Single-Center Real-World Study
    Article Snippet: All participants who initiated the CIQ system were previously using a Dexcom ® sensor (Dexcom, Inc., San Diego, CA, USA), while those who transitioned to the MM780G system were monitoring glucose with a Freestyle ® sensor (Abbott Laboratories, Chicago, IL, USA).

    Article Title: Impact of Automated Insulin Delivery Systems in Children and Adolescents with Type 1 Diabetes Previously Treated with Multiple Daily Injections: A Single-Center Real-World Study.
    Article Snippet: All participants who initiated the CIQ system were previously using a Dexcom® sensor (Dexcom, Inc., San Diego, CA, USA), while those who transitioned to the MM780G system were monitoring glucose with a Freestyle® sensor (Abbott Laboratories, Chicago, IL, USA).

    Clinical Proteomics:

    Article Title: First in Human Feasibility Study of an Insulin Patch Pump Combined With CGM-Insulin Delivery Cannula
    Article Snippet: .. Participants attended the clinical trials centre at 7:00 am on day 1 of the study after an overnight fast and inserting the Dexcom sensor the day prior to ensure appropriate warm-up time. ..



    Similar Products

    dexcom cgm sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom cgm sensor
    Dexcom Cgm Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/cgm+sensors/pm42156180-52-2-2
    Average 86 stars, based on 1 article reviews
    dexcom cgm sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g7 cgm sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g7 cgm sensor
    Dexcom G7 Cgm Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+g7+sensor/pm42156180-106-2-2
    Average 86 stars, based on 1 article reviews
    dexcom g7 cgm sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 platinum sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 platinum sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Platinum Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+g4+platinum/med_rxiv__64898__2026__05__13__26353094-140-16-16
    Average 86 stars, based on 1 article reviews
    dexcom g4 platinum sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom sensors  (Dexcom Inc)
    86
    Dexcom Inc dexcom sensors
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom Sensors, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+sensors/med_rxiv__64898__2026__05__13__26353094-32-26-26
    Average 86 stars, based on 1 article reviews
    dexcom sensors - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g6 sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g6 sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G6 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+g6+sensor/pm42108404-47-3-6
    Average 86 stars, based on 1 article reviews
    dexcom g6 sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    unblinded dexcom g7 sensor  (Dexcom Inc)
    86
    Dexcom Inc unblinded dexcom g7 sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Unblinded Dexcom G7 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+g7+sensor/pm42092238-19-34-35
    Average 86 stars, based on 1 article reviews
    unblinded dexcom g7 sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g7 sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g7 sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G7 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+g7+sensor/pmc13128380-112-1-1
    Average 86 stars, based on 1 article reviews
    dexcom g7 sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+sensor/pmc13065641-82-22-22
    Average 86 stars, based on 1 article reviews
    dexcom sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+sensor/dexcom+g4+sensor/pmc13065641-63-9-9
    Average 86 stars, based on 1 article reviews
    dexcom g4 sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Journal: medRxiv

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

    doi: 10.64898/2026.05.13.26353094

    Figure Lengend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Article Snippet: Our BGM comparison is restricted to a single arm of a single trial using the older Dexcom G4 Platinum sensor (mean absolute relative difference (MARD) ∼14%), which has lower accuracy than the Dexcom G6 (MARD ∼9%) used in three of our four datasets.

    Techniques: Software